I'm sure that it will in due course, but it would be better to be able to understand the numbers surrounding the agreement.The numbers are what would give the share price a kick along.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%